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OBJECTIVES: The objective of this analysis was to determine
the net economic beneﬁt to society from a SN60WF new tech-
nology intraocular lens (NTIOL) with an aspheric surface used
for the treatment of cataracts. METHODS: The incremental
costs of the aspheric SN60WF NTIOL were derived from the
additional $50 reimbursement paid by the U.S. Centers for
Medicare and Medicaid Services (CMS) for implantation of
NTIOLs in Medicare beneﬁciaries with cataracts. The economic
beneﬁts of the SN60WF were based on projected cost savings
from averted rear-end passenger vehicle collisions in the recipi-
ent population due to improved functional vision. Improved
functional vision was established using driving simulation results
comparing SN60WF recipients to patients implanted with a con-
ventional monofocal intraocular lens. A societal perspective and
a ten year time frame were used in the analysis. All costs and
beneﬁts were discounted at 3%. RESULTS: The incremental
costs to CMS for SN60WF implantation over the next decade
were estimated at $60 million U.S. dollars (USD). Driving sim-
ulation results indicated that SN60WF recipients performed
better than the control group in 34 of 36 driving tests. Further-
more SN60WF recipients were able to detect and identify poten-
tial road hazards from 0.5 to 1 second before the control patients
in 12 of the 36 tests. The economic beneﬁts from averted rear-
end passenger vehicle collisions were estimated in the range of
$105 to $158 million USD for the same 10 year period. Conse-
quently, the net economic beneﬁt to society was estimated
between $45 and $98 million USD over the next decade. A
threshold analysis revealed that a reduction in rear-end collisions
of 31% within the SA60WF recipient population was enough 
to offset the incremental NTIOL costs associated with the new
lens. CONCLUSION: Implantation of the NTIOL SN60WF in
cataract patients provides a net economic beneﬁt to society far
in excess of its incremental costs.
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OBJECTIVES: The objective of this study was to determine the
relative cost-effectiveness of three multifocal intraocular lenses
(IOLs) commonly implanted in cataract patients. METHODS: A
cost-effectiveness analysis was performed to determine the cost-
effectiveness ratios for the following three multifocal intraocular
lenses available in the U.S. health care market: an apodized dif-
fractive multifocal (ADM) IOL, a zonal refractive multifocal
(ZRM) IOL and an accommodating posterior chamber (APC)
IOL. The measure of effectiveness used was vision adjusted life
years (VALYs). VALYs are the product of the uncorrected near
visual acuity (UCNVA) provided by the IOLs and the average
life expectancy of the cataract patients. UCNVA, expressed in
decimal notation, and cost estimates were taken from the
medical literature. UCNVA was chosen as the measure of effect
because it is generally accepted that uncorrected distance visual
acuity outcomes are similar between the 3 alternative IOLs. The
economic perspective was that cataract patients enrolled in the
United States Medicare program. Only the direct incremental
costs of the multifocal IOLs were considered in the analysis. The
time span of the analysis was 14.2 years based on cataract
patients’ average life expectancy (ALE). No cost discounting was
performed because all incremental costs considered accrue in
year one. RESULTS: The average cost to patients for bilateral
multifocal IOL implantation was estimated at $4000. The
average UCNVAs, expressed in Snellen decimal notation, for the
ADM, ZRM and APC IOLs were 0.80, 0.57 and 0.7, respec-
tively. The VALY products of UCNVA and ALE for the ADM,
ZRM and APC IOLs were 11.36, 9.94 and 8.09 respectively. The
resultant VALY cost-effectiveness ratios for the ADM, ZRM and
APC IOLs were $352.11, $494.19 and $402.41, respectively.
CONCLUSION: Given the incremental cost associated with
multifocal IOLs the ADM IOL provides cataract patients with
the best value for their money.
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OBJECTIVES: To compare the effectiveness and related costs of
prostaglandins (PG) associated with either alpha-2 agonists or
carbonic anhydrase inhibitors (CAI), in the treatment of glau-
coma, according to the UK General Practitioner Research Data-
base (UK-GPRD). METHODS: Data were extracted on patients
diagnosed with ocular hypertension or glaucoma who had
undergone topical treatment, surgery or laser therapy. A subse-
quent selection identiﬁed patients receiving prostaglandins asso-
ciated with an alpha-2 agonist (PG + alpha-2) or CA inhibitor
(PG + CAI). Treatment failure was deﬁned as a prescription
change (addition or removal of a topical treatment). Times to
treatment failure were compared using an adjusted Cox model.
Drugs, clinic visits and glaucoma procedures were collected over
a ﬁxed period for a cost minimization analysis, performed from
the NHS perspective. RESULTS: Data on 56,612 patients were
extracted and 39,808 had received at least one topical prescrip-
tion for glaucoma. The treatment for 1384 patients was PG +
alpha-2 and for 4792 patients PG + CAI. Patient characteristics
did not differ signiﬁcantly between the two populations. The
average age at diagnosis was 69.0 years and 47.6% were male.
Treatment failure within one year occurred for 70.0% of patients
receiving PG + alpha-2 and for 59.5% receiving PG + CAI (p <
0.001). The hazard ratio 0.822 for failure, after adjusting on age,
gender, and comorbidities, was less with PG + CAI (p < 0.001)
than PG + alpha-2. The adjusted cost of PG + alpha-2 treatment
(£441 p.a.) did not differ signiﬁcantly (p = 0.23) from PG + CAI
(£413). CONCLUSION: According to UK GPRD information,
PG + CAI is more efﬁcient than PG + alpha-2 for treating glau-
coma patients. Patients remained under treatment longer with
PG + CAI, than with PG + alpha 2, at a similar cost.
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OBJECTIVES: To compare the effectiveness and costs of beta-
blockers, combined with alpha-2 agonists or carbonic anhydrase
inhibitors (CAI), as replacements for failed ﬁrst-line treatments
in glaucoma, according to the UK General Practitioner Research
Database (UK-GPRD). METHODS: Data on treated ocular
hypertension or glaucoma patients (topical, surgical or laser
treatments) were extracted. Target patients were prescribed beta-
blockers with alpha-2 agonists or CA inhibitors as replacements
for failed treatment regimens. A subsequent change of prescrip-
tion (addition or removal of a topical treatment) constituted a
